Navigation Links
The Leukemia & Lymphoma Society Issues Statement Regarding the Status of Iclusig (Ponatinib)
Date:11/1/2013

WHITE PLAINS, N.Y., Nov. 1, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is aware of the FDA's decision requesting Ariad Pharmaceuticals to suspend marketing and sales of Iclusig (ponatinib), a therapy for chronic myeloid leukemia (CML).  As suggested by the FDA, LLS encourages all patients currently receiving ponatinib to speak with their physician to discuss the risk and benefits of continuing treatment with the drug.  Those patients who are responding well to ponatinib, and who are not eligible for therapeutic alternatives, may be able to obtain ponatinib on a compassionate use basis, but need to speak with their oncologists immediately.

We are here to advise patients how the recent news applies to them and what discussions to have with their physicians.  Patients can contact LLS's Information Resource Center at 1-800-955-4572, Monday through Friday from 9 a.m. to 6 p.m. ET.

LLS recognizes the need and urgency for new treatments for CML.  In 2013, we committed $1.7 million to CML research ranging from basic science to clinical research on how best to use new therapies.

"The Leukemia & Lymphoma Society exists to find cures and ensure access to treatments for blood cancer patients," said Mark Velleca, MD, PhD, chief policy and advocacy officer for LLS.  "As such, we felt it was important to comment on this important access issue.  Working with CML physicians and other advocacy groups, we have requested that FDA facilitate continued access to ponatinib for certain patients – such as those in blast crisis – for whom interruption of therapy could be extremely detrimental."

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.  

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif
(914) 821-8958
andrea.greif@lls.org

Scott Orstad
(914) 821-8873
Scott.orstad@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Leukemia & Lymphoma Society and the Knight Cancer Institute Launch Groundbreaking Collaboration to Improve Outcomes for Acute Myeloid Leukemia Patients
2. OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017
3. St. Jude Childrens Research Hospital study yields new strategy against high-risk leukemia
4. The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million
5. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
6. Celebrating 25 Years and Counting: Leukemia and Lymphoma Societys "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients
7. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
8. The Leukemia & Lymphoma Society and Dana-Farber Cancer Institute to Bring Clinical Trials to Local Communities
9. The Leukemia & Lymphoma Society Applauds FDAs Approval of Lenalidomide for Patients with Relapsed or Refractory Mantle Cell Lymphoma
10. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
11. Leading Leukemia Experts: High Leukemia Treatment Costs May Be Harming Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 According to responses from U.S. oncologists that ... of patients with non-small cell lung cancer (NSCLC), treatment decisions ... genetic mutation status. The findings of the survey were presented ... #P3.02b ) at the 2016 World Conference on Lung ... The survey results revealed an overall high rate of ...
(Date:12/7/2016)... Dec. 7, 2016 Boehringer Ingelheim today ... patients with unresectable malignant pleural mesothelioma (MPM) met ... data, presented at the 17 th IASLC ... Vienna , showed nintedanib plus pemetrexed/cisplatin demonstrated ... pemetrexed/cisplatin, with a significantly improved PFS (9.4 vs ...
(Date:12/7/2016)... YORK , December 7, 2016 ... Pharmaceuticals PLC (NASDAQ: JAZZ ), Anthera Pharmaceuticals Inc. ... DNAI ), and AveXis Inc. (NASDAQ: AVXS ... Sector Index fell roughly 37% to reach a level equal ... it is down by approximately 14% for the year, it ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... 07, 2016 , ... “Fred Rides a Train” allows readers to tag along ... “Fred Rides a Train” is the creation of published author, Janet Morrison, who has ... in Michigan. The "Fred, the Dog" series is her first attempt at writing for ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Business ... Summit in Reston, VA on March 21-22, 2017. This premier event features business ... experiences from a cross-section of industries such as financial services, insurance, healthcare, manufacturing, ...
(Date:12/7/2016)... CA (PRWEB) , ... December 07, 2016 , ... NuevaCare, ... Francisco Peninsula region, is proud to announce new city-specific pages as part of its ... for the elderly, they often look, first, for local agencies serving their city. The ...
(Date:12/6/2016)... ... December 06, 2016 , ... People with Parkinson’s disease and ... a type of MRI, according to a study appearing online in the journal ... system characterized by tremors or trembling and stiffness in the limbs, impaired balance ...
(Date:12/6/2016)... Los Angeles, CA (PRWEB) , ... December 06, ... ... to suffer from erectile dysfunction because of a higher risk of serious health ... article on Star2.com. Dr. Peiman Soleymani of Beverly Hills Periodontics & ...
Breaking Medicine News(10 mins):